Vertex Pharmaceuticals Inc

More Details of Vertex Pharmaceuticals Inc Company

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Company Info

Company codeVRTX

Company nameVertex Pharmaceuticals Inc

IPO dateJul 24, 1991

Founded at1989

CEODr. Reshma Kewalramani

Number of employees6100

Security typeOrdinary Share

Fiscal year-endJul 24

Address50 Northern Avenue

CityBOSTON

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02210

Phone16173416393

Websitehttps://www.vrtx.com/

Company codeVRTX

IPO dateJul 24, 1991

Founded at1989

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

41.81K

+38.72%

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

23.68K

+38.42%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

Ms. Diana L. Mckenzie

Independent Director

8.63K

+485.29%

Mr. Lloyd A. Carney

Independent Director

6.32K

--

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.43K

--

Name

Name/Position

Position

Shareholding

Change

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

41.81K

+38.72%

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

23.68K

+38.42%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

TRIKAFTA

10.24B

92.91%

Other CF products

781.50M

7.09%

By RegionUSD

Name

Revenue

Proportion

United States

6.68B

60.66%

Europe

3.45B

31.34%

Other

881.30M

8.00%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

TRIKAFTA

10.24B

92.91%

Other CF products

781.50M

7.09%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Capital World Investors

11.02%

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.69%

Shareholder Statistics

Shareholder

Proportion

Capital World Investors

11.02%

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.69%

Type

Shareholder

Proportion

Investment Advisor

48.67%

Investment Advisor/Hedge Fund

37.50%

Pension Fund

2.67%

Research Firm

2.17%

Bank and Trust

1.87%

Sovereign Wealth Fund

1.44%

Hedge Fund

1.43%

Individual Investor

0.13%

Insurance Company

0.10%

Other

4.04%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2878

247.84M

96.41%

-3.72M

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

2023Q1

2468

250.11M

97.13%

-4.74M

2022Q4

2454

248.59M

96.73%

-7.80M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Capital World Investors

28.33M

11.02%

+1.51M

+5.65%

Dec 31, 2024

The Vanguard Group, Inc.

23.15M

9%

+102.48K

+0.44%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

14.33M

5.57%

-90.57K

-0.63%

Dec 31, 2024

State Street Global Advisors (US)

11.98M

4.66%

+163.16K

+1.38%

Dec 31, 2024

Capital Research Global Investors

10.43M

4.06%

+1.43M

+15.85%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.11M

3.54%

-1.25M

-12.07%

Dec 31, 2024

Wellington Management Company, LLP

5.92M

2.3%

+1.12M

+23.28%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.65M

2.2%

-287.65K

-4.85%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

5.33M

2.07%

+71.48K

+1.36%

Feb 28, 2025

JP Morgan Asset Management

4.62M

1.8%

-403.93K

-8.04%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

VanEck Biotech ETF

10.56%

Tema Neuroscience and Mental Health ETF

9.89%

Invesco Nasdaq Biotechnology ETF

8.48%

ProShares Ultra Nasdaq Biotechnology

8.08%

iShares Biotechnology ETF

7.22%

Indexperts Gorilla Aggressive Growth ETF

6.23%

Natixis Loomis Sayles Focused Growth ETF

4.96%

Franklin Genomic Advancements ETF

4.66%

Amplify AI Powered Equity ETF

4.21%

First Trust NYSE Arca Biotechnology Index Fund

3.65%

VanEck Biotech ETF

Proportion10.56%

Tema Neuroscience and Mental Health ETF

Proportion9.89%

Invesco Nasdaq Biotechnology ETF

Proportion8.48%

ProShares Ultra Nasdaq Biotechnology

Proportion8.08%

iShares Biotechnology ETF

Proportion7.22%

Indexperts Gorilla Aggressive Growth ETF

Proportion6.23%

Natixis Loomis Sayles Focused Growth ETF

Proportion4.96%

Franklin Genomic Advancements ETF

Proportion4.66%

Amplify AI Powered Equity ETF

Proportion4.21%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.65%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

509.500USD

Vertex Pharmaceuticals Inc

509.500

Overview

Company